Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Receivables (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Change in Receivables data on record, last reported at $1.9 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 1366.45% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.3 million, up 168.21%, while the annual FY2025 figure was $1.3 million, 168.21% up from the prior year.
  • Change in Receivables reached $1.9 million in Q4 2025 per CLDX's latest filing, up from -$974000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.4 million in Q4 2023 and bottomed at -$1.3 million in Q2 2021.
  • Average Change in Receivables over 5 years is $14157.9, with a median of $26000.0 recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 1403.8% in 2023, down 719.18% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$25000.0 in 2021, then skyrocketed by 732.0% to $158000.0 in 2022, then skyrocketed by 1403.8% to $2.4 million in 2023, then crashed by 106.4% to -$152000.0 in 2024, then skyrocketed by 1366.45% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $1.9 million in Q4 2025, -$974000.0 in Q2 2025, and $364000.0 in Q1 2025.